Al-Omari A, Al Mutair A, Alhumaid S, Salih S, Alanazi A, Albarsan H, Abourayan M, Al SM. The impact of antimicrobial stewardship program implementation at four tertiary private hospitals: results of a five-years pre-post analysis. Antimicrob Resist Infect Control. 2020;9(1):1–9.
Article Google Scholar
Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME, Devleesschauwer B, Cecchini M. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66.
Article PubMed PubMed Central Google Scholar
O’neill J. Review on antimicrobial resistance. Tackling drug-resistant infection globally: final report and recommendations. UK Government, Wellcome Trust. 2016.
Alrasheedy AA, Alsalloum MA, Almuqbil FA, Almuzaini MA, Aba Alkhayl BS, Albishri AS, Alharbi FF, Alharbi SR, Alodhayb AK, Alfadl AA. The impact of law enforcement on dispensing antibiotics without prescription: a multi-methods study from Saudi Arabia. Expert Rev Anti Infect Ther. 2020;18(1):87–97.
Article CAS PubMed Google Scholar
Al Mutair A, Alhumaid S, Al Alawi Z, Zaidi ARZ, Alzahrani AJ, Al-Tawfiq JA, Al-Shammari H, Rabaan AA, Khojah O, Al-Omari A. Five-year resistance trends in pathogens causing healthcare-associated infections at a multi-hospital healthcare system in Saudi Arabia, 2015–2019. J Global Antimicrob Resist. 2021;25:142–50.
Article Google Scholar
Balkhy HH, El-Saed A, Alshamrani MM, Alsaedi A, Al Nasser W, El Gammal A, Aljohany SM, Almunif S, Arabi Y, Alqahtani S. Ten-year resistance trends in pathogens causing healthcare-associated infections; reflection of infection control interventions at a multi-hospital healthcare system in Saudi Arabia, 2007–2016. Antimicrob Resist Infect Control. 2020;9(1):21.
Article PubMed PubMed Central Google Scholar
Al-Tawfiq JA, Rabaan AA, Saunar JV, Bazzi AM. Antimicrobial resistance of gram-negative bacteria: a six-year longitudinal study in a hospital in Saudi Arabia. J Infect Public Health. 2020;13:737–45.
Article PubMed Google Scholar
Almangour TA, Alenazi B, Ghonem L, Alhifany AA, Aldakheel BA, Alruwaili A. Inhaled colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria: a real-life experience in tertiary care hospitals in Saudi Arabia. Saudi Pharmaceut J. 2020;28(8):1009–13.
Article CAS Google Scholar
Batool S, Almaghaslah D, Alqahtani A, Almanasef M, Alasmari M, Vasudevan R, Attique S, Riaz F. Aetiology and antimicrobial susceptibility pattern of bacterial isolates in community acquired pneumonia patients at Asir region, Saudi Arabia. Int J Clin Pract. 2020;75:e13667.
PubMed Google Scholar
Bandy A, Almaeen AH. Pathogenic spectrum of blood stream infections and resistance pattern in gram-negative bacteria from Aljouf region of Saudi Arabia. PLoS ONE. 2020;15(6):e0233704.
Article CAS PubMed PubMed Central Google Scholar
Institute CaLS. M100|Performance standards for antimicrobial susceptibility testing. 30th Edn; 2020.
Ibrahim ME, Abbas M, Al-Shahrai AM, Elamin BK. Phenotypic characterization and antibiotic resistance patterns of extended-spectrum β-Lactamase-and AmpC β-lactamase-producing gram-negative bacteria in a referral hospital, Saudi Arabia. Canadian J Infect Dis Med Microbiol. 2019;2019:1–9.
Article Google Scholar
El-Badawy MF, Abdelwahab SF, Alghamdi SA, Shohayeb MM. Characterization of phenotypic and genotypic traits of carbapenem-resistant Acinetobacter baumannii clinical isolates recovered from a tertiary care hospital in Taif, Saudi Arabia. Infect Drug Resist. 2019;12:3113.
Article CAS PubMed PubMed Central Google Scholar
Farman M, Yasir M, Al-Hindi RR, Farraj SA, Jiman-Fatani AA, Alawi M, Azhar EI. Genomic analysis of multidrug-resistant clinical Enterococcus faecalis isolates for antimicrobial resistance genes and virulence factors from the western region of Saudi Arabia. Antimicrob Resist Infect Control. 2019;8(1):55.
Article PubMed PubMed Central Google Scholar
Aldrazi FA, Rabaan AA, Alsuliman SA, Aldrazi HA, Alabdalslam MJ, Alsadiq SA, Alhani HM, Bueid AS. ESBL expression and antibiotic resistance patterns in a hospital in Saudi Arabia: do healthcare staff have the whole picture? J Infect Public Health. 2020;13(5):759–66.
Article PubMed Google Scholar
Albarrag A, Shami A, Almutairi A, Alsudairi S, Aldakeel S, Al-Amodi A. Prevalence and molecular genetics of methicillin-resistant Staphylococcus aureus colonization in nursing homes in Saudi Arabia. Canadian J Infect Dis Med Microbiol. 2020;2020:1–6.
Article Google Scholar
Alqasim A, Jaffal AA, Almutairi N, Arshad M, Alyousef AA. Isolation, phenotypic and genotypic characterization of Escherichia coli from the bloodstream samples in Riyadh, Saudi Arabia. J King Saud Univ Sci. 2020;32(2):1464–9.
Article Google Scholar
Al Bshabshe A, Al-Hakami A, Alshehri B, Al-Shahrani KA, Alshehri AA, Al Shahrani MB, Assiry I, Joseph MR, Alkahtani A, Hamid ME. Rising Klebsiella pneumoniae infections and its expanding drug resistance in the intensive care unit of a tertiary Healthcare Hospital, Saudi Arabia. Cureus. 2020;12(8).
Alsaleh NA, Al-Omar HA, Mayet AY, Mullen AB. Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia. Saudi Pharmaceut J. 2020;28:1492–8.
Article CAS Google Scholar
Alnimr AM, Alamri AM. Antimicrobial activity of cephalosporin-beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant Pseudomonas aeruginosa strains. J Taibah Univ Med Sci. 2020;15(3):203.
PubMed PubMed Central Google Scholar
Alghoribi MF, Doumith M, Upton M, Al Johani SM, Alzayer M, Woodford N, Ellington MJ, Balkhy HH. Complete Genome Sequence of a Colistin-Resistant Uropathogenic Escherichia coli Sequence Type 131 fimH22 Strain Harboring mcr-1 on an IncHI2 Plasmid, Isolated in Riyadh, Saudi Arabia. Microbiology resource announcements. 2019;8(18).
Ishaqui AA, Khan AH, Sulaiman SAS, Alsultan MT, Khan I, Naqvi AA. Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1) pdm09 infection complications and rapidity of symptoms relief. Expert Rev Respir Med. 2020;14(5):533–41.
Article CAS PubMed Google Scholar
Aljihani SA, Alehaideb Z, Alarfaj RE, Alghoribi MF, Akiel MA, Alenazi TH, Al-Fahad AJ, Al Tamimi SM, Albakr TM, Alshehri A. Enhancing azithromycin antibacterial activity by encapsulation in liposomes/liposomal-N-acetylcysteine formulations against resistant clinical strains of Escherichia coli. Saudi J Biol Sci. 2020;27(11):3065–71.
Article CAS PubMed PubMed Central Google Scholar
Eed EM, Hawash YA, Khalifa AS, Alsharif KF, Alghamdi SA, Saber T, Ismail KA, Shehab-Eldeen SA. Molecular diagnosis of Helicobacter pylori antibiotic resistance in the Taif region, Saudi Arabia. Microbiol Immunol. 2019;63(6):199–205.
Article CAS PubMed Google Scholar
Al-Zahrani IA, Al-Ahmadi BM. Dissemination of VIM-producing Pseudomonas aeruginosa associated with high-risk clone ST654 in a tertiary and quaternary hospital in Makkah, Saudi Arabia. J Chemother. 2020;33:1–9.
Google Scholar
El-Badawy MF, Alrobaian MM, Shohayeb MM, Abdelwahab SF. Investigation of six plasmid-mediated quinolone resistance genes among clinical isolates of pseudomonas: a genotypic study in Saudi Arabia. Infect Drug Resist. 2019;12:915.
Article CAS PubMed PubMed Central Google Scholar
Balkhy HH, El-Saed A, Alshamrani MM, Alsaedi A, Al Nasser W, El Gammal A, Aljohany SM, Arabi Y, Alqahtani S, Bonnie HB. High Burden of resistant gram negative pathogens causing device-associated healthcare infections in a tertiary care setting in Saudi Arabia, 2008–2016. J Global Antimicrob Resist. 2020;23:26–32.
Article Google Scholar
El-Saed A, Balkhy HH, Alshamrani MM, Aljohani S, Alsaedi A, Al Nasser W, El Gammal A, Almohrij SA, Alyousef Z, Almunif S. High contribution and impact of resistant gram negative pathogens causing surgical site infections at a multi-hospital healthcare system in Saudi Arabia, 2007–2016. BMC Infect Dis. 2020;20:1–9.
Article Google Scholar
Farah SM, Alshehri MA, Alfawaz TS, Alasmeri FA, Alageel AA, Alshahrani DA. Trends in antimicrobial susceptibility patterns in King Fahad Medical City, Riyadh, Saudi Arabia. Saudi Med J. 2019;40(3):252.
Article PubMed PubMed Central Google Scholar
Haseeb A, Faidah HS, Bakhsh AR, AlMalki WH, Elrggal ME, Saleem F, ur Rahman S, Khan TM, Hassali MA. Antimicrobial resistance among pilgrims: a retrospective study from two hospitals in Makkah, Saudi Arabia. Int J Infect Dis. 2016;47:92–4.
Article PubMed Google Scholar
Asghar AH, Faidah HS. Frequency and antimicrobial susceptibility of gram-negative bacteria isolated from 2 hospitals in Makkah, Saudi Arabia. Saudi Med J. 2009;30(8):1017–23.
PubMed Google Scholar
Al-Tawfiq JA, Anani AA. Antimicrobial susceptibility pattern of bacterial pathogens causing urinary tract infections in a Saudi Arabian hospital. Chemotherapy. 2009;55(2):127–31.
Article CAS PubMed Google Scholar
Ibrahim ME. High antimicrobial resistant rates among gram-negative pathogens in intensive care units: a retrospective study at a tertiary care hospital in Southwest Saudi Arabia. Saudi Med J. 2018;39(10):1035.
Article PubMed PubMed Central Google Scholar
Almalki MA, Varghese R. Prevalence of catheter associated biofilm producing bacteria and their antibiotic sensitivity pattern. J King Saud Univ Sci. 2020;32(2):1427–33.
Article Google Scholar
Al Johani SM, Akhter J, Balkhy H, El-Saed A, Younan M, Memish Z. Prevalence of antimicrobial resistance among gram-negative isolates in an adult intensive care unit at a tertiary care center in Saudi Arabia. Ann Saudi Med. 2010;30(5):364–9.
Article PubMed PubMed Central Google Scholar
Memish ZA, Shibl AM, Kambal AM, Ohaly YA, Ishaq A, Livermore DM. Antimicrobial resistance among non-fermenting gram-negative bacteria in Saudi Arabia. J Antimicrob Chemother. 2012;67(7):1701–5.
Article CAS PubMed Google Scholar
Paquette F, Bernier-Jean A, Brunette V, Ammann H, Lavergne V, Pichette V, Troyanov S, Bouchard J. Acute kidney injury and renal recovery with the use of aminoglycosides: a large retrospective study. Nephron. 2015;131(3):153–60.
Article CAS PubMed Google Scholar
Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010;35(1):3–12.
Article PubMed Google Scholar
Balkhy HH, El-Saed A, El-Metwally A, Arabi YM, Aljohany SM, Al Zaibag M, Baharoon S, Alothman AF. Antimicrobial consumption in five adult intensive care units: a 33-month surveillance study. Antimicrob Resist Infect Control. 2018;7(1):156.
Article PubMed PubMed Central Google Scholar
Balkhy H, Al Othman A, Bonnie IB, Arabi Y, El-Saed A. Consumption of carbapenems in different intensive care units in a Saudi tertiary care hospital. Antimicrob Resist Infect Control. 2015;4(1):1-.
Abdallah M, Badawi M, Amirah MF, Rasheed A, Mady AF, Alodat M, Alharthy A. Impact of carbapenem restriction on the antimicrobial susceptibility pattern of Pseudomonas aeruginosa isolates in the ICU. J Antimicrob Chemother. 2017;72(11):3187–90.
Article CAS PubMed Google Scholar
Al Bshabshe A, Joseph MR, Awad El-Gied AA, Fadul AN, Chandramoorthy HC, Hamid ME. Clinical relevance and antimicrobial profiling of methicillin-resistant Staphylococcus aureus (MRSA) on routine antibiotics and ethanol extract of Mango Kernel (Mangifera indica L.). BioMed Res Int. 2020;2020:1–8.
Google Scholar
Page 2
Staphylococcus aureus
2015
2016
2017
2018
2019
Total
P-value*
(N = 903 isolates)
(N = 666 isolates)
(N = 940 isolates)
(N = 1,122 isolates)
(N = 1,222 isolates)
(N = 4,853 isolates)
T
S
S%
T
S
S%
T
S
S%
T
S
S%
T
S
S%
T
S
S%
AMP
191
64
33.5
131
52
39.7
169
93
55
157
87
55.4
222
63
28.4
870
359
41.3
0.828
CLX
677
544
80.4
444
331
74.5
797
656
82.3
747
679
90.9
887
735
82.9
3552
2945
82.9
0.649
CTN
230
109
47.4
209
89
42.6
266
134
50.4
266
154
57.9
252
161
63.9
1223
647
52.9
0.937
CIP
664
457
68.8
446
321
72
671
498
74.2
511
453
88.6
548
487
88.9
2840
2216
78
0.993
LVX
389
288
74
228
169
74.1
552
426
77.2
588
532
90.5
700
627
89.6
2457
2042
83.1
0.864
DCN
322
153
47.5
155
87
56.1
181
93
51.4
258
124
48.1
192
139
72.4
1108
596
53.8
0.983
TCN
514
305
59.3
489
423
86.5
891
838
94.1
1001
989
98.8
1201
1079
89.8
4096
3634
88.7
0.335
GMN
888
819
92.2
641
582
90.8
889
871
98
1022
955
93.4
1193
1098
92
4633
4325
93.4
0.775
EMN
722
696
96.4
558
473
84.8
791
740
93.6
971
813
83.7
991
929
93.7
4033
3651
90.5
0.659
CMN
804
780
97
576
513
89.1
896
871
97.2
1103
967
87.7
1187
1071
90.2
4566
4202
92
0.697
NFT
441
317
71.9
334
207
62
454
371
81.7
454
321
70.7
345
266
77.1
2028
1482
73.1
0.712
TMP-SMZ
595
463
77.8
591
524
88.7
865
819
94.7
1022
947
92.7
1201
996
82.9
4274
3749
87.7
0.542
LZD
903
903
100
641
625
97.5
790
773
97.8
1110
1003
90.4
1100
1076
97.8
4544
4380
96.4
0.931
VMN
901
895
99.3
651
624
95.9
938
931
99.3
1113
1109
99.6
1200
1181
98.4
4803
4740
98.7
0.721
MRSA
2015
2016
2017
2018
2019
Total
P-value*
(N = 359 isolates)
(N = 335 isolates)
(N = 284 isolates)
(N = 443 isolates)
(N = 310 isolates)
(N = 1,731 isolates)
T
S
S%
T
S
S%
T
S
S%
T
S
S%
T
S
S%
T
S
S%
AMP
90
13
14.4
44
8
18.2
51
7
13.7
74
15
20.3
69
21
30.4
328
64
19.5
0.814
CLX
116
72
62.1
147
86
58.5
147
81
55.1
311
138
44.4
290
141
48.6
1011
518
51.2
0.963
CTN
11
7
63.6
33
9
27.3
64
13
20.3
67
11
16.4
50
8
16
225
48
21.3
0.956
CIP
190
141
74.2
187
112
59.9
229
108
47.2
401
198
49.4
301
245
81.4
1308
804
61.5
0.924
LVX
55
31
56.4
99
46
46.5
187
75
40.1
366
131
35.8
260
115
44.2
967
398
41.2
0.693
DCN
222
110
49.5
189
122
64.6
280
141
50.4
410
191
46.6
307
154
50.2
1408
718
51
0.964
TCN
141
101
71.6
211
118
55.9
179
108
60.3
440
251
57
303
271
89.4
1274
849
66.6
0.860
GMN
291
121
41.6
277
129
46.6
151
116
76.8
432
216
50
300
284
94.7
1451
866
59.7
0.888
EMN
144
91
63.2
177
102
57.6
111
97
87.4
331
176
53.2
271
232
85.6
1034
698
67.5
0.878
CMN
220
93
42.3
254
113
44.5
161
108
67.1
411
203
49.4
300
264
88
1346
781
58
0.838
NFT
181
117
64.6
311
213
68.5
281
241
85.8
441
399
90.5
308
287
93.2
1522
1257
82.6
0.346
TMP-SMZ
233
88
37.8
268
114
42.5
229
108
47.2
409
201
49.1
290
227
78.3
1429
738
51.6
0.892
LZD
241
118
49
264
138
52.3
223
123
55.2
439
251
57.2
299
175
58.5
1466
805
54.9
0.974
VMN
299
121
40.5
285
138
48.4
258
123
47.7
440
251
57
305
175
57.4
1587
808
50.9
0.975
CoNS
2015
2016
2017
2018
2019
Total
P-value*
(N = 543 isolates)
(N = 276 isolates)
(N = 351 isolates)
(N = 426 isolates)
(N = 424 isolates)
(N = 2,020 isolates)
T
S
S%
T
S
S%
T
S
S%
T
S
S%
T
S
S%
T
S
S%
AMP
190
31
16.3
177
21
11.9
166
33
19.9
291
42
14.4
348
51
14.7
1172
178
15.2
0.948
CLX
164
88
53.7
190
64
33.7
289
96
33.2
408
146
35.8
333
114
34.2
1384
508
36.7
0.936
CTN
491
263
53.6
270
239
99.6
340
301
88.5
420
364
86.7
409
373
91.2
1930
1570
81.3
0.962
CIP
277
122
44
257
124
48.2
300
94
31.3
360
129
35.8
340
170
50
1534
639
41.7
0.991
LVX
130
46
35.4
211
56
26.5
288
142
49.3
420
173
41.2
211
85
40.3
1260
502
39.8
0.903
DCN
511
336
65.8
271
261
96.3
349
313
89.7
410
378
92.2
420
381
90.7
1961
1669
85.1
0.951
TCN
499
169
33.9
270
211
78.1
333
283
85
420
316
75.2
424
378
89.2
1946
1357
69.7
0.930
GMN
538
292
54.3
255
176
69
348
269
77.3
418
320
76.6
420
327
77.9
1979
1384
69.9
0.982
EMN
333
95
28.5
116
51
44
270
83
30.7
339
106
31.3
198
98
49.5
1256
433
34.5
0.966
CMN
531
255
48
266
156
58.6
269
235
87.4
399
282
70.7
339
293
86.4
1804
1221
67.7
0.981
NFT
170
77
45.3
233
99
42.5
331
225
68
411
250
60.8
400
344
86
1545
995
64.4
0.819
TMP-SMZ
369
153
41.5
276
199
72.1
350
298
85.1
400
349
87.3
407
327
80.3
1802
1326
73.6
0.831
LZD
541
535
98.9
276
273
98.9
351
351
100
426
426
100
424
424
100
2018
2009
99.6
0.967
VMN
543
537
98.9
276
276
100
351
351
100
426
426
100
424
424
100
2020
2014
99.7
0.968
Enterococcus species
2015
2016
2017
2018
2019
Total
P-value*
(N = 481 isolates)
(N = 370 isolates)
(N = 447 isolates)
(N = 411 isolates)
(N = 557 isolates)
(N = 2266 isolates)
T
S
S%
T
S
S%
T
S
S%
T
S
S%
T
S
S%
T
S
S%
AMP
460
305
66.3
330
252
76.4
422
378
89.6
377
318
84.4
533
508
95.3
2122
1761
83
0.539
CLX
469
280
59.7
340
299
87.9
430
364
84.7
388
381
98.2
499
433
86.8
2126
1757
82.6
0.618
CTN
281
61
21.7
277
79
28.5
414
110
26.6
350
124
35.4
444
151
34
1766
525
29.7
0.850
CIP
369
164
44.4
299
127
42.5
398
169
42.5
322
111
34.5
471
97
20.6
1859
668
35.9
0.965
LVX
379
243
64.1
310
182
58.7
441
305
69.2
401
275
68.6
333
188
56.5
1864
1193
64
0.928
DCN
244
32
13.1
177
20
11.3
288
44
15.3
200
59
29.5
347
67
19.3
1256
222
17.7
0.812
TCN
201
32
15.9
222
40
18
333
203
61
190
92
48.4
500
143
28.6
1446
510
35.3
0.213
GMN
298
113
37.9
191
76
39.8
430
123
28.6
310
152
49
499
183
36.7
1728
647
37.4
0.972
EMN
411
145
35.3
301
42
14
357
153
42.9
188
53
28.2
331
65
19.6
1588
458
28.8
0.824
CMN
177
28
15.8
191
45
23.6
299
61
20.4
191
77
40.3
189
81
42.9
1047
292
27.9
0.506
NFT
322
116
36
355
300
84.5
438
393
89.7
391
364
93.1
541
482
89.1
2047
1655
80.9
0.306
TMP-SMZ
280
63
22.5
339
276
81.4
409
291
71.1
336
273
81.3
534
376
70.4
1898
1279
67.4
0.646
LZD
481
470
97.7
370
370
100
447
447
100
411
411
100
557
556
99.8
2266
2254
99.5
0.874
VMN
481
237
49.3
370
361
97.6
440
435
98.9
410
364
88.8
550
537
97.6
2251
1934
85.9
0.517
Overall
2015
2016
2017
2018
2019
Total
P-value*
(N = 2286 isolates)
(N = 1647 isolates)
(N = 2022 isolates)
(N = 2402 isolates)
(N = 2513 isolates)
(N = 10,870 isolates)
T
S
S%
T
S
S%
T
S
S%
T
S
S%
T
S
S%
T
S
S%
AMP
931
413
44.4
682
333
48.8
808
511
63.2
899
462
51.4
1172
643
54.9
4492
2362
52.6
0.971
CLX
1426
984
69
1121
780
69.6
1663
1197
72
1854
1344
72.5
2009
1423
70.8
8073
5728
71
0.874
CTN
1013
440
43.4
789
446
56.5
1084
558
51.5
1103
653
59.2
1155
693
60
5144
2790
54.2
0.933
CIP
1500
884
58.9
1189
684
57.5
1598
869
54.4
1594
891
55.9
1660
999
60.2
7541
4327
57.4
0.969
LVX
953
608
63.8
848
453
53.4
1468
948
64.6
1775
1111
62.6
1504
1015
67.5
6548
4135
63.1
0.610
DCN
1299
631
48.6
792
490
61.9
1098
591
53.8
1278
752
58.8
1266
741
58.5
5733
3205
55.9
0.939
TCN
1355
607
44.8
1192
792
66.4
1736
1432
82.5
2051
1648
80.4
2428
1871
77.1
8762
6350
72.5
0.556
GMN
2015
1345
66.7
1364
963
70.6
1818
1379
75.9
2182
1643
75.3
2412
1892
78.4
9791
7222
73.8
0.905
EMN
1610
1027
63.8
1152
668
58
1529
1073
70.2
1829
1148
62.8
1791
1324
73.9
7911
5240
66.2
0.965
CMN
1732
1156
66.7
1287
827
64.3
1625
1275
78.5
2104
1529
72.7
2015
1709
84.8
8763
6496
74.1
0.922
NFT
1114
627
56.3
1233
819
66.4
1504
1230
81.8
1697
1334
78.6
1594
1379
86.5
7142
5389
75.5
0.032
TMP-SMZ
1477
767
51.9
1474
1113
75.5
1853
1516
81.8
2167
1770
81.7
2432
1926
79.2
9403
7092
75.4
0.595
LZD
2166
2026
93.5
1551
1406
90.7
1811
1694
93.5
2386
2091
87.6
2380
2231
93.7
10,294
9448
91.8
0.875
VMN
2224
1790
80.5
1582
1399
88.4
1987
1849
92.6
2389
2163
90
2479
2357
93.5
10,661
9558
89.1
0.901
N Number of pathogens causing healthcare-associated infections, T number of tested isolates, S number of susceptible pathogens, S (%) percentage of susceptible pathogens, MRSA methicillin-resistant Staphylococcus aureus, CoNS coagulase-negative staphylococci, AMP ampicillin, CLX cloxacillin, CTN cefoxitin, CIP ciprofloxacin, LVX levofloxacin, NFT nitrofurantoin, EMN erythromycin, CMN clindamycin, TMP-SMZ trimethoprim-sulfamethoxazole, GMN gentamicin, DCN doxycycline, TCN tetracycline, VMN vancomycin, LZD linezolid
*Multivariate analysis of variance (MANOVA) for resistance trend
